Latest clinical trials of reovirus in pancreatic cancer patients

Version française

REOLYSIN® is a formulation of human reovirus type 3 Dearing (T3D) which is being developed by Oncolytics Biotech Inc. for a number of cancer indications including pancreatic ductal adenocarcinoma (PDAC) (see here). It has entered clinical trials for pancreatic cancer in combination with a number of drugs including standard chemotherapeutics and newer immune checkpoint targeting antibodies (Pembrolizumab: trade name KEYTRUDA®) (See table 1).

 

reo

 

ClinicalTrials.gov links

NCT02620423, NCT01280058, NCT00998322

 

Update of NCT01280058 (NCI-8601) trial based on data collected up to January 19, 2016 from the NCI

http://www.oncolyticsbiotech.com/news/oncolytics-biotech-inc-reports-updated-data-from-randomized-phase-2-study-of-reolysin-in-pancreatic-cancer/?elqTrackId=f8f1f697d24a4f1b8a0b57d84b98e11a&elq=2fe69a4b469249f18ccf3b23e1db27fe&elqaid=15230&elqat=1&elqCampaignId=9

The overall survival rate was increased. A proportion of patients receiving REOLYSIN® were alive beyond three years, whereas no patients in the control group survived beyond one year.

 

Final results from Oncolytics Biotech Inc.’s NCT00998322 (REO 017) Phase II study

http://www.oncolyticsbiotech.com/news/oncolytics-biotech-inc-collaborators-present-final-data-from-reo-017-clinical-study-in-pancreatic-cancer/

http://www.oncolyticsbiotech.com/wp-content/uploads/2015/07/panc-poster-June22-2015.pdf

Overall survival rates were increased and the immune checkpoint protein PD-L1 was demonstrated to be increased in post-treatment tumours. This formed a rationale for the use of Pembrolizumab (KEYTRUDA®) in the new NCT02620423 (REO 024) trial.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s